Yissum - Research Development Company of the Hebrew University

Platform Technology for Total Synthesis of Spiro-Epoxy-Fused Natural Molecules

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

The outlined synthetic methodology will offer conceptually novel perspective, enabling to deliver desired targets via cascade sequence of cyclization reactions from easily accessible key molecule. A simplified access will thus be provided to a wide range of spiro-epoxy-fused natural product and their structural analogues
Project ID : 6-2014-2984

Yissum - Research Development Company of the Hebrew University
Yissum - Research Development Company of the Hebrew University

Description of the technology

Category

Chemistry & Materials

Keywords

Synthetic, natural, cyclization

Current development stage

General list: TRL4 Technology validated in lab

Application

  • Many important biochemical compounds and drugs of natural origin contain spirofuranone ring structures (these structures exist among carbohydrates, terpenoids, vitamins, alkaloids, glycosides and antibiotics). All derived from a simple precursor via intramolecular cascade transformation.
  • Numerous studies have led to a wide variety of modern drugs and potential pharmaceutical candidates that share the compact tricyclic systems, as alliacanes, arteannuins, teucrolivins
  • These molecules are naturally produced in small quantities, there is great interest in mass-producing them through a synthetic pathway.
  • Unfortunately, access to a large number of these target molecules and their structural analogues is either unknown or hindered by their multistep syntheses.

Our Innovation

Novel synthetic methodology that will enable to deliver desired targets via cascade sequence of cyclization reactions from easily accessible key molecule. Our novel approach includes platform technology to synthesize libraries of compounds.

  • Effectively synthesizing natural materials that have always been hard to synthesize.
  • Faster synthesis process.
  • A simplified access to a wide range of spiro-epoxy-fused natural product and their structural analogues.
  • Unite the families of described molecular frames under a common synthetic strategy
  • Enables scaffolds constructed through simple and straightforward cyclization

Technology

  • There are several molecular domains that can be considered as common.
  • For example, in natural TPRV1 agonist we focus mainly on the presence of three distinct regions, conceptually similar:
  • The Vanilloid scaffold, which consists of the Vanilloid (3-methoxy-4-hydroxy) moiety and is vital for the biological activity.
  • The Carbonylic segment which is integrated with the carbonylic moiety, and responsible for specific hydrogen bond interactions between the substrate and the enzyme.
  • The lipophilic domain which is significantly different in all agonists, yet crucial for their high potency.
  • It also devises a simple means for building the tricyclic skeletons in a rapid and efficient manner.
  • In addition, Pd(II)-catalyzed cascade reactions were profitably selected as a key step for the total synthesis of several natural products. Using unprecedented Pd-catalyzed cascade Wacker-Hecklactonization-cyclization sequence, rapid assembly of spiranoid lactones was achieved.

Fig.1 : Natural products from diverse biological origins share tricyclic spiranoid ring systems

Fig. 2: Natural TRPV1 agonists (exo- and endo-Vanilloids): structural difference and similarity

Opportunity

Short synthetic process to be used on families of natural products.

Broad natural diversity of compounds available.

Pain treatment – reducing the hypersensitivity of nociceptors

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Dmitry Tsvelikhovsky
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.